Provided by Tiger Trade Technology Pte. Ltd.

Jupiter Neurosciences

0.6183
+0.01893.15%
Post-market: 0.61830.00000.00%16:10 EST
Volume:128.38K
Turnover:76.74K
Market Cap:21.29M
PE:-2.69
High:0.6250
Open:0.5804
Low:0.5700
Close:0.5994
52wk High:3.33
52wk Low:0.4800
Shares:34.43M
Float Shares:14.88M
Volume Ratio:0.92
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2303
EPS(LYR):-0.0848
ROE:--
ROA:-354.94%
PB:370.72
PE(LYR):-7.29

Loading ...

Jupiter Neurosciences Inc - Announces Strategic Initiative for Glp-1 Users

THOMSON REUTERS
·
Jan 28

Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users

GlobeNewswire
·
Jan 28

Jupiter Neurosciences to Present at DealFlow Discovery Conference in Atlantic City

Reuters
·
Jan 27

Jupiter Neurosciences Secures $1.86 Million Second Tranche Financing from Yorkville

Reuters
·
Dec 24, 2025

Jupiter Neurosciences Inc. Held Annual Shareholder Meeting

Reuters
·
Dec 23, 2025

Jupiter Neurosciences to Present at NobleCon21 Emerging Growth Conference

Reuters
·
Dec 03, 2025

BRIEF-Jupiter Neurosciences Files Rospectus Related To Resale Of Up To 10 Million Shares Of Our Common Stock By Selling Stockholder

Reuters
·
Nov 27, 2025

Jupiter Neurosciences Inc - Files Rospectus Related to Resale of up to 10 Mln Shares of Our Common Stock by Selling Stockholder

THOMSON REUTERS
·
Nov 27, 2025

Jupiter Neurosciences Issues Amended SEC Filing

Reuters
·
Nov 21, 2025

Jupiter Neurosciences price target lowered to $25 from $30 at Greenridge

TIPRANKS
·
Nov 06, 2025

Jupiter receives FDA clearance of IND application to initiate Phase 2 trial

TIPRANKS
·
Nov 05, 2025

BRIEF-Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL in Parkinson’s Disease

Reuters
·
Nov 05, 2025

Jupiter Neurosciences Inc - Expects Trial Enrollment to Begin in Early 2026

THOMSON REUTERS
·
Nov 05, 2025

Jupiter Neurosciences Inc - Proceeds to Support Phase 2 Parkinson's Trial and Nugevia Growth

THOMSON REUTERS
·
Oct 27, 2025

Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing

GlobeNewswire
·
Oct 27, 2025

Jupiter Neurosciences Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Oct 18, 2025

Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador

GlobeNewswire
·
Sep 15, 2025

Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements

GlobeNewswire
·
Aug 26, 2025

Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador

GlobeNewswire
·
Aug 19, 2025

Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience

GlobeNewswire
·
Aug 11, 2025